Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States.

Christine PoulosAhmed M SolimanSibel TekinSanjay K Agarwal

Published in: Expert review of pharmacoeconomics & outcomes research (2020)

Patients' preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.

Keyphrases

chronic pain
pain management
end stage renal disease
ejection fraction
neuropathic pain
newly diagnosed
physical activity
climate change
case report
decision making
risk assessment
spinal cord